Direct oral anticoagulants (DoaCs) offer significant benefits for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. these agents are simpler to use than others, as they do not require routine laboratory monitoring and dose adjustment. moreover, DoaCs have been shown to reduce severe bleedings, and especially intracranial bleedings, as compared to vitamin k antagonists. real-life clinical data confirmed these benefits that had previously been shown in randomized clinical trials.
This article describes several advances made in the dyslipidemia and cardiovascular prevention fields. These novelties pertain to the three steps of prevention: prediction including screening for two common, but often ignored, genetic abnormalities, namely familial hypercholesterolemia and elevated lipoprotein(a) levels, planning with the emergence in recommendations of a new target called "non-HDL cholesterol or non-HDL-C" in addition to the conventional "LDL-cholesterol or LDL-C" target, and prescription with the possible option of combining statins with other therapeutic classes.
The mechanism of action of the most commonly prescribed immunosuppressive drugs, as well as their dosage and adverse effects, are highligted in this article, with particular emphasis on toxicity prevention and treatment monitoring by general practitioners.